TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06628479

Intervention type: OTHER
Intervention: interleukin, enzyme, hormone
Description: Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
Study: NCT06628674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core muscle exercise
Description: Patients in experiment group will do core muscle exercise with online interactive videos

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pelvic muscle exercise
Description: Patients in experiment group will do pelvic muscle exercise without online interactive videos
Study: NCT06631274

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: counseling
Description: The intervention (IVY; Intervention for Victimized Youth) is an 8 week group counseling intervention delivered in a virtual environment.
Study: NCT06631547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Hormonal treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The usual head trauma care
Description: the basic treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The usual head trauma care
Description: the basic treatment
Study: NCT06333015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista EY Beyond IOL
Description: enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enVista MX60E monofocal IOL
Description: enVista MX60E monofocal IOL
Study: NCT04889066

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy
Description: 24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiation Therapy
Description: 24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study: NCT06629753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differentiated service delivery model
Description: The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.
Study: NCT06628466

Intervention type: DRUG
Intervention: Nuberol Forte
Description: Quality of Life study
Study: NCT06630182

Intervention type: OTHER
Intervention: Bortner self-questionnaire
Description: 14 items

Intervention type: OTHER
Intervention: Self-questionnaire BFI-10
Description: 10 items
Study: NCT06631131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization with clear aligners supported by Class II elastics
Description: Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization with clear aligners supported by miniscrew
Description: Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
Study: NCT06631118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B
Description: Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B
Description: Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
Study: NCT06629883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REPS w/BANDS
Description: This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
Study: NCT06700993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual in Collaborative Care or Integrated Behavioral Health
Description: Treatment as Usual will be whatever primary care and behavioral health services are standardly implemented for adolescents or young adults experiencing suicidality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connections model
Description: The Connections model applies the Aeschi Model of suicide care to Collaborative Care or other Integrated Behavioral Health by centering the patient's clinical narrative, focusing treatment on the patient's unique drivers of suicide, and maximizing collaboration while maintaining the standards of suicide assessment and management expected by accrediting bodies.
Study: NCT06694389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083
Description: Suspension for injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride suspension for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Influenza Vaccine
Description: Aqueous injectable (SC) or suspension for injection (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 Vaccine
Description: Suspension for injection
Study: NCT06705413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiome diet
Description: The participants will receive Microbiome diet for three consecutive menstrual cycles. A three-phase diet (21-day phase, 28-day phase and maintenance phase) will be followed by the experimental group which contains some food restrictions and addition for certain food types which may improve gut health.
Study: NCT06704945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary surgery
Description: BCS only. Ommission of axillary surgery. No axillary surgery after neoadjuvant chemotherapy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary surgery
Description: BCS with SLNB(+/-ALND)
Study: NCT04889066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study: NCT06711497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global postural reeducation exercises
Description: Subjects will be trained on global postural reeducation exercises (GPR) and active neck exercises. At each session, they will maintain two different lying postures to stretch anterior and posterior muscle chain and one standing posture to integrate the postural correction into activity of daily living (ADL.Initially, without gravity load, a lying posture was applied to the anterior muscle chain for approximately 15 min, then another lying posture to the posterior muscle chain for other 15 min, and finally the patients worked in a standing posture for postural integration under a gravity load for 5 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep neck flexor activation exercise
Description: Subjects will be trained on deep neck flexor activation using pressure biofeedback and active neck exercises . The pressure sensor will be put under the neck and will be asked to de gentle nod as if saying yes so that the pressure sensor measures 2mmHg above baseline (20mmHg), then 4mmHg, followed by 6mmHg,8mmHg, and 10 mmHg without rests in between. the pressure sensor should read 30mmHg at the end of the movement sequence. Patient will hold each increment for 2 seconds, 10 seconds total after all 5 increments. Highest level achieved will be repeated with the correct form until a total of 10 reps with 10-second holds will be achieved in three series with 30 seconds of interval between the series plus active neck flexor exercise
Study: NCT06712654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 75mg TID
Description: receiving orally AP306 75mg (one tablet), three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 100mg TID
Description: receiving orally AP306 100 mg (one tablet), three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 125mg TID
Description: receiving orally AP306 125 mg (one tablet), three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 125mg BID
Description: receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 150mg BID
Description: receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TID
Description: receiving orally one placebo tablet of AP306, three times a day
Study: NCT06712290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celgene
Description: CTM Boost (CTM Biomedical, Miami, FL) is a decellularized Human Cellular and Tissue Based Allograft (HCT/P) derived from placental connective tissue. It is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is regulated as a minimally-manipulated biologic by the FDA and is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is administered applied into the tissue via injection.~Participant will undergo a single injection of 2.0cc of the injectable CTM allograft, administered using a 20G needle in the subacromial space. 3mL of ropivacaine will be mixed into the syringe prior to administration of the injection. Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or intra-articular (into the joints) use. It may be used to treat many different types of inflammatory conditions. In this study, a 2.0cc dose injection of Kenalog-40 will be administered directly into the subacromial space using a 20G needle. 3mL of ropivacaine will be injected along with the steroid (as part of the same injection). Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used.
Study: NCT06712446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT
Description: Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: EFT
Description: Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency rTMS
Description: TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling . For dlPFC, we will measure position F3. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. Intermittent theta burst stimulation (iTBS) (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the resting motor threshold (RMT) and will last \~3 minutes. Participants will receive 2 sessions of iTBS to the dlPFC brain region with a 15-20-minute interval between sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham frequency rTMS
Description: Participants will receive sham TMS to the dlPFC. They may feel the TMS from the A/P coil electrodes, but there will not be any real stimulation of the brain.
Study: NCT06712667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee with different amounts of caffeine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee with different amounts of caffeine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee with different amounts of caffeine.
Study: NCT06711640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUCEMYRA (lofexidine) tablets
Description: Tablets. Participants weighing ≥45 kg: three 0.18 mg tablets (0.54 mg) four times per day (QID). Participants weighing ≥30 to \<45 kg: two 0.18 mg tablets (0.36 mg) QID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUCEMYRA (lofexidine) tablets
Description: Tablets. Participants weighing ≥45 kg: three 0.18 mg tablets (0.54 mg) four times per day (QID). Participants weighing ≥30 to \<45 kg: two 0.18 mg tablets (0.36 mg) QID.
Study: NCT06711120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively
Description: During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively
Description: During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.
Study: NCT06711848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A web-based educational intervention on oral cancer
Description: This intervention will involve administering education, via a website, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
Study: NCT06121947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The DBS electrodes are implanted into MLR.
Description: MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.
Study: NCT06121947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The electrodes are implanted into the patient's vagus nerve
Description: A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
Study: NCT06711848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A mobile health app-based educational intervention on oral cancer
Description: This intervention will involve administering education, via a mhealth application prototype, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
Study: NCT05840731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Study: NCT06712316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Study: NCT06712316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Study: NCT06712316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion